Skip to main content
Funded Studies

Development of SHG to Discover Drugs to Selectively Block AlphaS toxicity

Abnormal aggregation of normal or genetically mutated alpha-synuclein protein has been proposed as one possible mechanism for PD. Drugs that can target this abnormal change in the structure of the alpha-synuclein protein may prove beneficial as neuroprotective treatments. Dr. Salafsky has developed a technology, called second-harmonic generation (SHG) that can detect changes in a protein’s conformation. Using this technology, he will create a laboratory screening assay that can be used to screen for compounds that can block abnormal changes in alpha-synuclein conformation. If successful, the assay can then be used in large-scale drug screening approaches.

Final Outcome

Dr. Salafsky successfully developed his screening assay and received supplemental funding to conduct compound screens.


  • Joshua Salafsky, PhD

    Burlingame, CA United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.